{"id":"0997b9796b5e","type":"article","url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","title":"Bloeddrukinterventie en -controle in SPRINT nader geanalyseerd","title_en":"Blood Pressure Intervention and Control in SPRINT.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["ambulante-bloeddrukmeting","bloeddrukbehandeling","bradycardie"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17233","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17233","authors":["William C Cushman","Robert J Ringer","Carlos J Rodriguez","Gregory W Evans","Jeffrey T Bates","Jeffrey A Cutler","Amret Hawfield","Dalane W Kitzman","Ilya M Nasrallah","Suzanne Oparil","John Nord","Vasilios Papademetriou","Karen Servilla","Peter Van Buren","Paul K Whelton","Jeff Whittle","Jackson T Wright"],"significance":6,"published":"2022-09-01","source_date":"2022-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/","https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/"],"congress":"","summary_en":"This detailed SPRINT analysis described the pharmacological strategy used to achieve intensive blood pressure control, showing that on average 2.8 antihypertensives were needed versus 1.8 for standard treatment.","created":"2026-07-03T10:29:54Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Gedetailleerde analyse van SPRINT beschreef hoe de intensieve bloeddrukbehandeling werd bereikt: gemiddeld 2,8 antihypertensiva versus 1,8 in de standaardgroep. De meest gebruikte middelen waren ACE-remmers/ARB's, gevolgd door thiaziden en calciumantagonisten.","abstract_original":"BACKGROUND: The SPRINT (Systolic Blood Pressure Intervention Trial) demonstrated reductions in major cardiovascular disease events and mortality with an intensive systolic blood pressure (SBP) goal intervention. However, a detailed description of the blood pressure intervention, antihypertensive medication usage, blood pressure levels, and rates and predictors of blood pressure control has not been reported previously. METHODS: Hypertensive participants (n=9361) 50 years and older with elevated cardiovascular disease risk were randomized 1:1 to SBP goal <120 mm Hg or SBP goal <140 mm Hg. Guideline-recommended antihypertensive medications and dosing were provided at no cost. Intensive group participants were started on at least 2 medications, and medications were adjusted monthly until SBP goal was achieved, if feasible. Standard group participants were treated to achieve SBP 135 to 139 mm Hg. RESULTS: Baseline blood pressure (median±interquartile range) was 138±19/78±16 mm Hg. For intensive group participants, percent at goal rose from 8.9% at baseline to 52.4% at 6 months and average antihypertensive medications rose from 2.2 to 2.7; SBP was <120 mm Hg in 61.6% and <130 mm Hg in 80.0% at their final visit. For the standard group participants, percent at goal rose from 53.0% at baseline to 68.6% at 6 months, while antihypertensive medications fell from 1.9 to 1.8. From 6 to 36 months, median SBP was stable at 119±14 mm Hg for intensive and 136±15 mm Hg for standard participants, with stable numbers of medications. Few predictors of SBP control were found in multiple regression models. CONCLUSIONS: These results may inform and help replicate the benefits of SPRINT in clinical practice. REGISTRATION: URL: http://www. CLINICALTRIALS: gov; Unique identifier: NCT01206062."}